Mechanistic insights into the inhibition of microtubule affinity-regulating kinase 4 by Syringic acid: A computational and experimental study.

Microtubule affinity regulating kinase 4 (MARK4) is a vital protein kinase that serves as a dual target in cancer and neurodegenerative diseases. It is implicated in the development of tauopathies and also linked to the pathogenesis of several cancer types, implying its importance. Syringic acid is a naturally occurring phenolic molecule that has shown significant efficacies in cancer and neurodegenerative diseases by modulating several key pathways. Thus, the present study aims to investigate the inhibitory potential of syringic acid against the protein kinase MARK4, employing a combination of experimental and computational approaches. Molecular docking revealed the binding of syringic acid in the MARK4's binding pocket, interacting with key functional residues of the protein kinase. Molecular dynamic simulation (MD) studies demonstrated the conformational dynamics and structural stability of MARK4 upon the binding of syringic acid. In silico findings were further complemented by experimental assays. Enzyme inhibition assay showed that syringic acid effectively inhibits MARK4 with an IC50 value of 4.32 μM. Fluorescence binding assays revealed a strong binding affinity (K = 2.8 × 106 M-1). The findings of our study establish syringic acid as a potent MARK4 inhibitor, providing a perfect platform for its use in tackling MARK4-associated diseases.

• Publication year

  2025

• Venue

  International Journal of Biological Macromolecules

• Publication date

  2025-04-01

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1016/j.ijbiomac.2025.142812PMID 40216145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinases and their derived inhibitors from natural products.

  2025cited by this paper
• Multi‐Targeting Phytochemicals for Alzheimer's Disease

  2025cited by this paper
• Investigating Pyruvate Dehydrogenase Kinase 3 Inhibitory Potential of Myricetin Using Integrated Computational and Spectroscopic Approaches

  2024cited by this paper
• Role of Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 Signaling in Liver and Metabolic Diseases

  2024cited by this paper
• MARK4 aggravates cardiac dysfunction in mice with STZ-induced diabetic cardiomyopathy by regulating ACSL4-mediated myocardial lipid metabolism

  2024cited by this paper
• Harnessing memantine in Alzheimer's disease therapy through inhibition of microtubule affinity-regulating kinase: Mechanistic insights.

  2024cited by this paper
• Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease

  2024cited by this paper
• Medicinal Plants in the Treatment of Respiratory Diseases and their Future Aspects.

  2024cited by this paper
• protein kinase inhibitors as Targeted therapy for glioblastoma: A meta-analysis of randomized controlled clinical trials.

  2024cited by this paper
• Investigating MARK4 inhibitory potential of Bacopaside II: Targeting Alzheimer's disease.

  2023cited by this paper
• Tau, tau kinases, and tauopathies: An updated overview

  2023cited by this paper
• Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy.

  2022cited by this paper
• Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics

  2022cited by this paper
• Phosphorylation-Induced Structural Reorganization in Tau-Paired Helical Filaments.

  2021cited by this paper
• Microtubule affinity regulating kinase 4: A promising target in the pathogenesis of atherosclerosis

  2021cited by this paper
• MARK4 controls ischaemic heart failure through microtubule detyrosination

  2021cited by this paper
• Using molecular docking and molecular dynamics to investigate protein-ligand interactions

  2021cited by this paper
• Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update.

  2021cited by this paper
• Virtual Screening Approach to Identify High-Affinity Inhibitors of Serum and Glucocorticoid-Regulated Kinase 1 among Bioactive Natural Products: Combined Molecular Docking and Simulation Studies

  2020cited by this paper
• InstaDock: A single-click graphical user interface for molecular docking-based virtual high-throughput screening

  2020cited by this paper
• Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition

  2020cited by this paper
• MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer’s Disease Therapy

  2020cited by this paper
• Strong and Weak Hydrogen Bonds in Protein–Ligand Recognition

  2019cited by this paper
• Syringic acid (SA) ‒ A Review of Its Occurrence, Biosynthesis, Pharmacological and Industrial Importance.

  2018cited by this paper
• MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.

  2017cited by this paper
• Strategies for the exploration of free energy landscapes: Unity in diversity and challenges ahead

  2017cited by this paper
• MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells

  2017cited by this paper
• miR‐515‐5p controls cancer cell migration through MARK4 regulation

  2016cited by this paper
• Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.

  2016cited by this paper
• Crystal structure of microtubule affinity-regulating kinase 4 catalytic domain in complex with a pyrazolopyrimidine inhibitor.

  2015cited by this paper
• GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers

  2015cited by this paper
• MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies

  2014cited by this paper
• Role of Individual MARK Isoforms in Phosphorylation of Tau at Ser262 in Alzheimer’s Disease

  2013cited by this paper
• The Importance of Tau Phosphorylation for Neurodegenerative Diseases

  2013cited by this paper
• Elucidating Human Phosphatase-Substrate Networks

  2013cited by this paper
• Exploring the Free Energy Landscape: From Dynamics to Networks and Back

  2009cited by this paper
• The tau of MARK: a polarized view of the cytoskeleton.

  2009cited by this paper
• Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes?

  2008cited by this paper
• Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

  2008cited by this paper
• Interaction of different polyphenols with bovine serum albumin (BSA) and human salivary alpha-amylase (HSA) by fluorescence quenching.

  2007cited by this paper
• Role of Solvent Accessibility in Structure Based Drug Design

  2005cited by this paper
• Tau pathology in Alzheimer disease and other tauopathies.

  2005cited by this paper
• Role of tau protein in both physiological and pathological conditions.

  2004cited by this paper
• Interactions between PAMAM dendrimers and bovine serum albumin.

  2003cited by this paper
• Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis.

  2001cited by this paper
• Regulation of microtubule-associated proteins.

  2001cited by this paper
• Microtubule‐Affinity Regulating Kinase (MARK) Is Tightly Associated with Neurofibrillary Tangles in Alzheimer Brain: A Fluorescence Resonance Energy Transfer Study

  2000cited by this paper
• REVIEW: tau protein pathology in Alzheimer’s disease and related disorders

  1999cited by this paper
• Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins.

  1994cited by this paper
• Phosphorylation affects the ability of tau protein to promote microtubule assembly.

  1984cited by this paper
• Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly.

  1977cited by this paper
• A protein factor essential for microtubule assembly.

  1975cited by this paper

• Benzo[d]thiazole derivatives as microtubule affinity-regulating kinase 4 (MARK4) inhibitors: Synthesis, characterization, biological evaluation, and computational studies

  2025cites this paper
• Targeting ubiquitin-specific peptidase 22 (USP22) as a nexus for drug repurposing in anticancer therapeutic development

  2025influential citation